PolyPeptide Group AG
SIX:PPGN

Watchlist Manager
PolyPeptide Group AG Logo
PolyPeptide Group AG
SIX:PPGN
Watchlist
Price: 27.95 CHF 4.1% Market Closed
Market Cap: 921.9m CHF
Have any thoughts about
PolyPeptide Group AG?
Write Note

Intrinsic Value

The intrinsic value of one PPGN stock under the Base Case scenario is 24.99 CHF. Compared to the current market price of 27.95 CHF, PolyPeptide Group AG is Overvalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PPGN Intrinsic Value
24.99 CHF
Overvaluation 11%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
PolyPeptide Group AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PPGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PPGN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
PolyPeptide Group AG

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about PolyPeptide Group AG

Provide an overview of the primary business activities
of PolyPeptide Group AG.

What unique competitive advantages
does PolyPeptide Group AG hold over its rivals?

What risks and challenges
does PolyPeptide Group AG face in the near future?

Has there been any significant insider trading activity
in PolyPeptide Group AG recently?

Summarize the latest earnings call
of PolyPeptide Group AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for PolyPeptide Group AG.

Provide P/S
for PolyPeptide Group AG.

Provide P/E
for PolyPeptide Group AG.

Provide P/OCF
for PolyPeptide Group AG.

Provide P/FCFE
for PolyPeptide Group AG.

Provide P/B
for PolyPeptide Group AG.

Provide EV/S
for PolyPeptide Group AG.

Provide EV/GP
for PolyPeptide Group AG.

Provide EV/EBITDA
for PolyPeptide Group AG.

Provide EV/EBIT
for PolyPeptide Group AG.

Provide EV/OCF
for PolyPeptide Group AG.

Provide EV/FCFF
for PolyPeptide Group AG.

Provide EV/IC
for PolyPeptide Group AG.

Show me price targets
for PolyPeptide Group AG made by professional analysts.

What are the Revenue projections
for PolyPeptide Group AG?

How accurate were the past Revenue estimates
for PolyPeptide Group AG?

What are the Net Income projections
for PolyPeptide Group AG?

How accurate were the past Net Income estimates
for PolyPeptide Group AG?

What are the EPS projections
for PolyPeptide Group AG?

How accurate were the past EPS estimates
for PolyPeptide Group AG?

What are the EBIT projections
for PolyPeptide Group AG?

How accurate were the past EBIT estimates
for PolyPeptide Group AG?

Compare the revenue forecasts
for PolyPeptide Group AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of PolyPeptide Group AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of PolyPeptide Group AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of PolyPeptide Group AG compared to its peers.

Compare the P/E ratios
of PolyPeptide Group AG against its peers.

Discuss the investment returns and shareholder value creation
comparing PolyPeptide Group AG with its peers.

Analyze the financial leverage
of PolyPeptide Group AG compared to its main competitors.

Show all profitability ratios
for PolyPeptide Group AG.

Provide ROE
for PolyPeptide Group AG.

Provide ROA
for PolyPeptide Group AG.

Provide ROIC
for PolyPeptide Group AG.

Provide ROCE
for PolyPeptide Group AG.

Provide Gross Margin
for PolyPeptide Group AG.

Provide Operating Margin
for PolyPeptide Group AG.

Provide Net Margin
for PolyPeptide Group AG.

Provide FCF Margin
for PolyPeptide Group AG.

Show all solvency ratios
for PolyPeptide Group AG.

Provide D/E Ratio
for PolyPeptide Group AG.

Provide D/A Ratio
for PolyPeptide Group AG.

Provide Interest Coverage Ratio
for PolyPeptide Group AG.

Provide Altman Z-Score Ratio
for PolyPeptide Group AG.

Provide Quick Ratio
for PolyPeptide Group AG.

Provide Current Ratio
for PolyPeptide Group AG.

Provide Cash Ratio
for PolyPeptide Group AG.

What is the historical Revenue growth
over the last 5 years for PolyPeptide Group AG?

What is the historical Net Income growth
over the last 5 years for PolyPeptide Group AG?

What is the current Free Cash Flow
of PolyPeptide Group AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for PolyPeptide Group AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
PolyPeptide Group AG

Balance Sheet Decomposition
PolyPeptide Group AG

Current Assets 292.6m
Cash & Short-Term Investments 48.5m
Receivables 68.9m
Other Current Assets 175.2m
Non-Current Assets 372.3m
Long-Term Investments 6.2m
PP&E 334m
Intangibles 16.5m
Other Non-Current Assets 15.6m
Current Liabilities 183.6m
Accounts Payable 41.6m
Other Current Liabilities 142m
Non-Current Liabilities 121.4m
Long-Term Debt 68.5m
Other Non-Current Liabilities 52.9m
Efficiency

Earnings Waterfall
PolyPeptide Group AG

Revenue
327.3m EUR
Cost of Revenue
-297m EUR
Gross Profit
30.3m EUR
Operating Expenses
-44.9m EUR
Operating Income
-14.6m EUR
Other Expenses
-14m EUR
Net Income
-28.6m EUR

Free Cash Flow Analysis
PolyPeptide Group AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

PolyPeptide is navigating a transition year in 2023, undertaking aggressive expansion with the aim to become a large-scale CDMO. They've offset COVID-19 revenues, indicating strong core business growth, and advanced key partnerships, particularly in metabolics. The product pipeline has grown, with 31 phase III projects set to ensure mid-term growth. Increased customer demand is fueling CapEx expansion, funded by planned additional financing. The company has an operational improvement plan underway, though the first half saw a sharp profitability decline due to inventory write-offs and negative cost absorption. The second half of the year is focused on fulfilling customer demand, expecting higher revenue and EBITDA, and improving operational productivity, with profitability projected to recover as the scale-up continues.

What is Earnings Call?
Fundamental Scores

PPGN Profitability Score
Profitability Due Diligence

PolyPeptide Group AG's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Positive Revenue Growth Forecast
Positive Gross Profit
Positive 1-Year Revenue Growth
Negative Operating Income
37/100
Profitability
Score

PolyPeptide Group AG's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

PPGN Solvency Score
Solvency Due Diligence

PolyPeptide Group AG's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
50/100
Solvency
Score

PolyPeptide Group AG's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PPGN Price Targets Summary
PolyPeptide Group AG

Wall Street analysts forecast PPGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PPGN is 32.64 CHF with a low forecast of 19.19 CHF and a high forecast of 47.25 CHF.

Lowest
Price Target
19.19 CHF
31% Downside
Average
Price Target
32.64 CHF
17% Upside
Highest
Price Target
47.25 CHF
69% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PPGN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for PPGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PPGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

PolyPeptide Group AG Logo
PolyPeptide Group AG

Country

Switzerland

Industry

Life Sciences Tools & Services

Market Cap

921.9m CHF

Dividend Yield

0%

Description

PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. The company is headquartered in Zug, Zug and currently employs 1,041 full-time employees. The company went IPO on 2021-04-29.

Contact

ZUG
Zug
Dammstrasse 19
+41417232040.0
www.polypeptide.com

IPO

2021-04-29

Employees

1 041

Officers

Chief Executive Officer
Mr. Juan Jose Gonzalez
Chief Financial Officer
Mr. Marc Augustin
Director of Global Operations
Mr. Jens Fricke
Director of Corporate Finance
Rene Vestergaard
Director Global Innovation & Technology
Mr. Olivier Ludemann-Hombourger
General Counsel & Corporate Secretary
Ms. Christina Del Vecchio
Show More
Chief Human Resources Officer
Ms. Monika Casanova
Head of Technical Department - Braine
Christophe Chevalier
Chief Information Security Officer & Global IT Services VC
Krister Svard
Head of Internal Audit
Rebecca Weil
Show Less

See Also

Discover More
What is the Intrinsic Value of one PPGN stock?

The intrinsic value of one PPGN stock under the Base Case scenario is 24.99 CHF.

Is PPGN stock undervalued or overvalued?

Compared to the current market price of 27.95 CHF, PolyPeptide Group AG is Overvalued by 11%.

Back to Top